Therefore, we developed a CAR T-cell product targeting both CD20 and CD30, for patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including patients who progressed following conventional CD19-targeted CAR T cells. The gene discussed is TNFRSF8; the disease is B-cell non-Hodgkin lymphoma.